Highlights from the SWG

The most relevant and impactful activities of SWG

The most relevant and impactful activities of the SWG include those related to the Guideline development project. There were regular meetings with the Guidelines Expert Panel Committee. The EHA SWG business meetings to discuss the progress in the development of the Guidelines for the use and reporting of patient-reported outcomes in clinical trials took place on July 1, 2021, and Nov 15, 2022. Several meetings with Cochrane Haematology and the University of Cologne specialists involved in the systematic review process have been conducted. The first systematic review underpinning the guidelines in multiple myeloma has been published in Cancers and the guidelines manuscript has been submitted for publication. Other systematic reviews for these guidelines are in progress. The chapter on the multiple myeloma PRO guidelines has been finalized. Chapters for other hematological malignancies are in progress.

The most relevant advancements in SWG area

  • Organization of SWG Session at EHA-2022

Title: “Evidence based patient-reported outcomes in clinical decision-making”

Chair: Esther Oliva (Italy)

- Narrative Medicine-  Sam Salek (UK)

- PROs in myeloproliferative neoplasms: examining the evidence - Tatyana Ionova (Russia)

- PROs in lymphoproliferative neoplasms: examining the evidence - Edward Laane (Estonia)

- The role of advocacy patient representatives in mediating communication to patients with chronic malignancies - Natacha Bolonas (Spain)

  • The SWG board members contributed to the EHA-SWG Scientific Meeting "Patient-centered Geriatric Hematology" virtual meeting on October 6-7, 2021, with the presentation entitled “Patient-Reported Outcome Measurement (PROMs) in hematological malignancies”.
  • The SWG board members contributed to the AIL-AIPASIM hematological malignancy patient congress in Rome, Italy on October 25, 2022.

The top 3 follow-up activities will be given priority in the next year

  • Finalization of the guidelines for PRO assessment in lymphoproliferative neoplasms, myeloproliferative neoplasms, and myelodysplastic neoplasms are the top follow-up activities prioritized in the next year.
  • Preparation of the SWG session within EHA-2023.
  • Publication of the systematic review articles in lymphomas, leukemias, and MDS